Growth factor specialist upsizes series B with help from Pfizer

Belgian biotech Agomab Therapeutics has extended its series B financing round with an additional close of $40.5 million, bringing the total to $114 million.

The company is researching growth factor biology to address fibrosis with novel treatments which can repair tissue structure and restore organ function.